Asco 2020 – Tagrisso shows what early targeting can do | Evaluate
TAGRISSO® (osimertinib) | AURA3 Study
Metastatic NSCLC Efficacy of TAGRISSO® (osimertinib)
ADAURA Establishes Adjuvant Osimertinib as a New Standard of Care for Early-Stage EGFR-Mutated NSCLC
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
Efficacy of Resectable NSCLC – TAGRISSO® (osimertinib) Nurse Center
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status - Journal of Thoracic Oncology
TAGRISSO® (osimertinib) | FLAURA
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study | Future Oncology
TAGRISSO 40 mg film-coated tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
TAGRISSO 40 mg film-coated tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc)
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer - European Journal of Cancer
Metastatic NSCLC Efficacy of TAGRISSO® (osimertinib)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Osimertinib in Advanced Lung Cancer with EGFR Mutations - National Cancer Institute
TAGRISSO® (osimertinib) | AURA3 Study
New England Journal of Medicine publishes results of Phase III FLAURA trial in the 1st-line treatment of EGFR-mutated non-small cell lung cancer
TAGRISSO® (osimertinib) | FLAURA
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer
Metastatic NSCLC Efficacy of TAGRISSO® (osimertinib)
Efficacy of TAGRISSO® (osimertinib) in resectable EGFRm NSCLC
Metastatic NSCLC Efficacy of TAGRISSO® (osimertinib)
